The scale up of pharmaceutical innovation is facing an even more challenging environment than imagined. Within this context some initiatives have arisen across EU with the willingness to combine an always complex equation: early access to innovation for the patients that may benefit the most at a fair price, health care expenditure cost control, and incentives to pharma and biotech innovation for health solutions.

New and detailed proposals from the Pricing and Reimbursement Advisor Committee (CAPF) has been published in Spain. These proposals will be the basis for an open discussion about the implications of these measures in the future of the Pricing and Reimbursement processes and negotiations in Spain.